Clinical Trials Insight: 700023421
Phase of Trial: Phase I
Latest Information Update: 02 Mar 2010
At a glance
- Drugs Tucidinostat (Primary)
- Indications Cancer; Lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chipscreen Biosciences; HUYA Bioscience International
- 02 Mar 2010 Chipscreen aims to launch the drug in China by the end of 2010, according to a media release from the company.
- 23 Oct 2008 Status changed from active, no longer recruiting to completed based on information provided in a HUYA Biosciences International media release.
- 23 Oct 2008 Results have been reported in a HUYA Biosciences International media release; this data has also been presented at the Cambridge Healthtech Institute Fall Conference.